BioLineRX Says CLARITY Trial of BL-1020 Did Not Meet Primary Efficacy Endpoint, to Discontinue Study
March 20, 2013 at 09:01 AM EDT
BioLineRx (NASDAQ: BLRX ), a biopharmaceutical development company, today announced that results from a pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, indicate that the trial would not meet the pre-specified primary efficacy endpoint. After conferring with the
